DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/969fc7/gilenya_fingolimo) has announced the addition of GlobalData's new report "Gilenya (Fingolimod), Laquinimod and Cladribine - Impact on the Multiple Sclerosis (MS) Treatment Landscape" to their offering.
Gilenya (Fingolimod), Laquinimod and Cladribine - Impact on the Multiple Sclerosis (MS) Treatment Landscape provides key information on current available treatment of Multiple Sclerosis, drivers and barriers for the future MS market and how the novel pipeline molecules will drive the global market
Scope
Data and information on the impact of Gilenya (Fingolimod), Laquinimod and Cladribine on the current treatment landscape of Multiple Sclerosis
Reasons to buy
Develop business strategies by understanding the trends and developments in Multiple Sclerosis market
Key Topics Covered:
1 Table of Contents 2 Summary
3 Multiple Sclerosis Overview
3.1 Disease Overview
3.2 Diagnosis
3.3 Epidemiology
4 Current Therapy Options
5 Unmet Need
6 Drivers and Barriers
6.1 Drivers
6.2 Barriers
7 Gilenya, Laquinimod and Cladribine - First Oral Therapies for Multiple Sclerosis
7.1 Gilenya Clinical Trial Details - TRANSFORMS and FREEDOMS
7.2 Laquinimod Clinical Trial Details - BRAVO and ALLEGRO
7.3 Cladribine - CLARITY, ONWARDS and ORACLE
8 Multiple Sclerosis Market
9 Appendix
For more information visit http://www.researchandmarkets.com/research/969fc7/gilenya_fingolimo.
CONTACT:
Research and Markets
Laura Wood, Senior Manager
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
KEYWORDS:
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical Professional Services Other Professional Services
MEDIA:
| Logo |